A clinical evaluation of patients with known mutations (plasminogen and factor XII) with a focus on prophylactic treatment

CONCLUSION: This is one of the first descriptions of the clinical outcomes as a response to prophylactic treatment with lanadelumab in HAE-nC1-INH patients with a known mutation. The therapeutic management of HAE-1 and HAE-2 should also be the basis of HAE-nC1-INH, including prophylaxis.PMID:38086754 | DOI:10.1080/09546634.2023.2290362
Source: Journal of Dermatological Treatment - Category: Dermatology Authors: Source Type: research